Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA, Pipal RW, Benz-Weeden AM, Brewster JT 2nd, Cook A, Crooks AL, Cruz C, Dwulet NC, Gaudino JJ, Golec D, Harrison JA, Hartley DP, Hassanien SH, Hicken EJ, Kahn D, Laird ER, Lemieux C, Lewandowski N, McCown J, McDonald MG, McNulty O, Mou TC, Nguyen P, Oko L, Opie LP, Otten J, Peck SC, Polites VC, Randall SD, Rosen RZ, Savechenkov P, Simpson H, Singh A, Sparks D, Wickersham K, Wollenberg L, Wong CE, Wong J, Wu WI, Elsayed MSA, Hinklin RJ, Tang TP.
Bumpers QA, et al. Among authors: kahn d.
J Med Chem. 2024 Aug 22;67(16):14466-14477. doi: 10.1021/acs.jmedchem.4c01232. Epub 2024 Aug 1.
J Med Chem. 2024.
PMID: 39088797